Coya Therapeutics Fireside Chat with David Sherman and LifeSci Summer Symposium
Houston, TX., — Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, presented a corporate overview by Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, at the LifeSci Summer Symposium held virtually on July 21, 2021. LifeSci Summer […]
Coya Therapeutics, Inc. KOL Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) featuring Dr. Stanley Appel (Houston Methodist Neurological Institute)
Coya Therapeutics, Inc. KOL Webinar on ALS001 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) featuring Dr. Stanley Appel (Houston Methodist Neurological Institute) Location: Webcast Link
Coya Therapeutics at the Oppenheimer Rare & Orphan Disease Summit
Houston, TX., — Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, presented a corporate overview by Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, at the Oppenheimer Rare & Orphan Disease Summit held virtually on May 21, […]
